121 related articles for article (PubMed ID: 18155893)
1. Optimum overall times II: Extended modelling for head and neck radiotherapy.
Fowler JF
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):113-26. PubMed ID: 18155893
[TBL] [Abstract][Full Text] [Related]
2. Is there an optimum overall time for head and neck radiotherapy? A review, with new modelling.
Fowler JF
Clin Oncol (R Coll Radiol); 2007 Feb; 19(1):8-22. PubMed ID: 17305251
[TBL] [Abstract][Full Text] [Related]
3. Derivation of the optimum dose per fraction from the linear quadratic model.
Jones B; Tan LT; Dale RG
Br J Radiol; 1995 Aug; 68(812):894-902. PubMed ID: 7551788
[TBL] [Abstract][Full Text] [Related]
4. Modelling the optimal radiotherapy regime for the control of T2 laryngeal carcinoma using parameters derived from several datasets.
Roberts SA; Hendry JH; Slevin NJ
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1173-82. PubMed ID: 9392560
[TBL] [Abstract][Full Text] [Related]
5. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations.
Fowler JF
Radiother Oncol; 1990 Jun; 18(2):165-81. PubMed ID: 2367691
[TBL] [Abstract][Full Text] [Related]
6. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules.
Fowler JF; Harari PM; Leborgne F; Leborgne JH
Radiother Oncol; 2003 Nov; 69(2):161-8. PubMed ID: 14643953
[TBL] [Abstract][Full Text] [Related]
7. The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.
Robertson AG; Robertson C; Boyle P; Symonds RP; Wheldon TE
Eur J Cancer; 1993; 29A(4):501-10. PubMed ID: 8435200
[TBL] [Abstract][Full Text] [Related]
8. A challenge to traditional radiation oncology.
Fowler JF; Tomé WA; Fenwick JD; Mehta MP
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1241-56. PubMed ID: 15519797
[TBL] [Abstract][Full Text] [Related]
9. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
Appelt AL; Vogelius IR; Bentzen SM
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
[TBL] [Abstract][Full Text] [Related]
10. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy.
Hendry JH; Bentzen SM; Dale RG; Fowler JF; Wheldon TE; Jones B; Munro AJ; Slevin NJ; Robertson AG
Clin Oncol (R Coll Radiol); 1996; 8(5):297-307. PubMed ID: 8934049
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules.
Wyatt RM; Jones BJ; Dale RG
Br J Radiol; 2008 Jul; 81(967):549-63. PubMed ID: 18378526
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase I/II trial of two variants of accelerated fractionated radiotherapy regimens for advanced head and neck cancer: results of RTOG 88-09.
Fu KK; Clery M; Ang KK; Byhardt RW; Maor MH; Beitler JJ
Int J Radiat Oncol Biol Phys; 1995 Jun; 32(3):589-97. PubMed ID: 7790243
[TBL] [Abstract][Full Text] [Related]
13. A rationale for fractionation for slowly proliferating tumors such as prostatic adenocarcinoma.
Fowler JF; Ritter MA
Int J Radiat Oncol Biol Phys; 1995 May; 32(2):521-9. PubMed ID: 7751194
[TBL] [Abstract][Full Text] [Related]
14. The reduction of tumour control with increasing overall time: mathematical considerations.
Jones B; Dale RG
Br J Radiol; 1996 Sep; 69(825):830-8. PubMed ID: 8983587
[TBL] [Abstract][Full Text] [Related]
15. Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone.
Gasinska A; Fowler JF; Lind BK; Urbanski K
Acta Oncol; 2004; 43(7):657-66. PubMed ID: 15545186
[TBL] [Abstract][Full Text] [Related]
16. A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization.
Kim M; Stewart RD; Phillips MH
Med Phys; 2015 Nov; 42(11):6671-8. PubMed ID: 26520757
[TBL] [Abstract][Full Text] [Related]
17. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy by multiple fractions per day (MFD) in head and neck cancer: acute reactions of skin and mucosa.
Van der Schueren E; Van den Bogaert W; Vanuytsel L; Van Limbergen E
Int J Radiat Oncol Biol Phys; 1990 Aug; 19(2):301-11. PubMed ID: 2394609
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
[TBL] [Abstract][Full Text] [Related]
20. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.
van Leeuwen CM; Oei AL; Crezee J; Bel A; Franken NAP; Stalpers LJA; Kok HP
Radiat Oncol; 2018 May; 13(1):96. PubMed ID: 29769103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
